Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
11.13
-0.20 (-1.77%)
At close: Feb 21, 2025, 4:00 PM
11.20
+0.07 (0.63%)
After-hours: Feb 21, 2025, 4:29 PM EST
Wave Life Sciences Revenue
Wave Life Sciences had revenue of $-7.68M in the quarter ending September 30, 2024, a decrease of -115.60%. This brings the company's revenue in the last twelve months to $53.61M, down -37.29% year-over-year. In the year 2023, Wave Life Sciences had annual revenue of $113.31M with 3,005.10% growth.
Revenue (ttm)
$53.61M
Revenue Growth
-37.29%
P/S Ratio
26.07
Revenue / Employee
$200,037
Employees
268
Market Cap
1.70B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 113.31M | 109.66M | 3,005.10% |
Dec 31, 2022 | 3.65M | -37.32M | -91.09% |
Dec 31, 2021 | 40.96M | 20.89M | 104.03% |
Dec 31, 2020 | 20.08M | 4.09M | 25.61% |
Dec 31, 2019 | 15.98M | 1.57M | 10.89% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
WVE News
- 16 days ago - Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity - GlobeNewsWire
- 6 weeks ago - Wave Life Sciences Is A Buy On Pipeline Prospects - Seeking Alpha
- 2 months ago - Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity - GlobeNewsWire
- 2 months ago - Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Wave Life Sciences to Present at Jefferies London Healthcare Conference - GlobeNewsWire
- 3 months ago - Wave Life Sciences Ltd. (WVE) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs - GlobeNewsWire
- 4 months ago - Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst - Seeking Alpha